Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 824-lymphoma-and-non-acute-leukemia-with-other-procedures-with-cc
    Ask Trek AI about this page

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    DRG 824 includes hospital stays for lymphoma and non-acute leukemia involving other procedures with at least one Complication or Comorbidity, reflecting moderate clinical complexity. Correct grouping affects inpatient reimbursement under Medicare by aligning payment with procedure intensity and patient acuity.

    Customize your policy alerts

    Sign up for drg 824 policy alerts

    Get alerted when payer policies referencing 824 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 824 Overview

    DRG 824 covers hospital admissions for patients with lymphoma and non-acute leukemia who undergo other significant diagnostic or therapeutic procedures and have at least one Complication or Comorbidity. This Diagnosis-Related Group captures cases with moderate clinical complexity where the procedures and presence of Complication or Comorbidity affect resource use. It matters for Medicare inpatient payment because the grouping determines relative reimbursement for hospitals under the Inpatient Prospective Payment System, reflecting procedure intensity and patient acuity. Accurate coding of principal diagnosis, secondary diagnoses, and procedures is central to correct assignment to this Diagnosis-Related Group and corresponding payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Studies of inpatient-adjunct procedural strategies and perioperative management for lymphoma and chronic (non-acute) leukemia patients undergoing diagnostic or therapeutic procedures: these trials assess protocols for procedures commonly coded as “other procedures” (such as lymph node excisional biopsy, tunneled central line placement, bone marrow or targeted biopsy, or palliative surgical/embolization procedures) to reduce peri-procedural complications and length of stay. The patient population includes hospitalized adults with lymphoma or indolent leukemias who have comorbidities or treatment-related cytopenias that increase procedural risk; outcomes measured include bleeding, infection, transfusion needs, and 30-day readmission. This research is directly relevant to hospitals and payers because reducing procedure-related complications and short inpatient stays can lower costs, improve DRG case-mix management, and inform appropriate bundling of services under the DRG.
    • Comparative effectiveness trials of inpatient systemic or supportive therapies aimed at management of disease-related complications in non-acute leukemia and lymphoma: these studies compare approaches such as dose-modified chemotherapy, targeted outpatient-to-inpatient transition strategies, or intensified supportive care regimens (growth factors, antimicrobial prophylaxis strategies, transfusion thresholds) for patients admitted with symptomatic disease or treatment complications. The enrolled group is hospitalized patients with lymphoma or chronic leukemia experiencing complications like symptomatic cytopenias, febrile neutropenia risk, or tumor-related organ compromise; primary questions evaluate clinical recovery time, avoidance of intensive care, and short-term mortality. Results guide clinicians and payers on which inpatient therapeutic pathways produce better short-term outcomes and resource utilization for this DRG, informing care protocols and reimbursement considerations.
    • Post-discharge outcomes and care-coordination studies focusing on readmission reduction and transition-of-care models for lymphoma and non-acute leukemia patients with complications: these observational and interventional studies examine discharge planning, early outpatient follow-up, home-based nursing or transfusion services, and telehealth monitoring to prevent readmission among high-risk patients. The population includes patients under DRG 824 discharged after an admission involving procedures or treatment with concurrent complications or comorbidities (CC), with endpoints like 30- and 90-day readmission rates, emergency visits, and pharmacy utilization. Findings are important for providers and payers because effective post-discharge models can decrease costly readmissions, improve patient outcomes, and influence value-based payment strategies tied to this DRG.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    828-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.